Catalyst Biosciences, Inc. Company Review & Valuation
About Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications.
Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant.
Catalyst Biosciences, Inc.
has collaboration agreement with Pfizer, Inc.
for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials.
The company has strategic research collaboration with Mosaic Biosciences, Inc.
to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases.
The company is headquartered in South San Francisco, California.